Published in JAMA on March 13, 2006
Nitric oxide synthases: regulation and function. Eur Heart J (2011) 4.71
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol (2006) 4.02
Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol (2007) 3.96
Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem (2010) 2.07
Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc (2009) 1.88
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J (2012) 1.79
Efficacy of homocysteine-lowering therapy with folic Acid in stroke prevention: a meta-analysis. Stroke (2010) 1.75
Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV (2015) 1.75
Regression and stabilization of advanced murine atherosclerotic lesions: a comparison of LDL lowering and HDL raising gene transfer strategies. J Mol Med (Berl) (2011) 1.73
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther (2011) 1.68
LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J Clin Invest (2010) 1.67
Genetic variants at chromosome 9p21 and risk of first versus subsequent coronary heart disease events: a systematic review and meta-analysis. J Am Coll Cardiol (2014) 1.61
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J (2009) 1.59
Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf (2010) 1.56
A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int (2007) 1.54
Family history of coronary heart disease and the incidence and progression of coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis (2013) 1.52
Cytochrome P450 and gene activation--from pharmacology to cholesterol elimination and regression of atherosclerosis. Eur J Clin Pharmacol (2008) 1.52
Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest (2012) 1.51
Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem (2010) 1.43
miR-135a Suppresses Calcification in Senescent VSMCs by Regulating KLF4/STAT3 Pathway. Curr Vasc Pharmacol (2016) 1.42
The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress. Cardiovasc Drugs Ther (2007) 1.41
Relationship between left coronary artery bifurcation angle and restenosis after stenting of the proximal left anterior descending artery. Coron Artery Dis (2016) 1.39
Graft vessel disease following heart transplantation: a systematic review of the role of statin therapy. World J Surg (2014) 1.38
Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag (2008) 1.30
High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation (2010) 1.29
Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ Res (2012) 1.29
Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PLoS One (2011) 1.25
Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med (2010) 1.17
Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol (2011) 1.17
The Pathway Less Traveled: Moving from Candidate Genes to Candidate Pathways in the Analysis of Genome-Wide Data from Large Scale Pharmacogenetic Association Studies. Curr Pharmacogenomics Person Med (2008) 1.16
IVUS-based imaging modalities for tissue characterization: similarities and differences. Int J Cardiovasc Imaging (2011) 1.15
Ca2+ regulatory mechanisms of exercise protection against coronary artery disease in metabolic syndrome and diabetes. J Appl Physiol (1985) (2011) 1.14
Subclinical atherosclerosis: what it is, what it means and what we can do about it. Int J Clin Pract (2008) 1.14
Regression of aortic valve stenosis by ApoA-I mimetic peptide infusions in rabbits. Br J Pharmacol (2008) 1.12
Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities. Br J Pharmacol (2012) 1.07
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther (2010) 1.06
Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin. Ann Clin Microbiol Antimicrob (2012) 1.06
Mapping genes that predict treatment outcome in admixed populations. Pharmacogenomics J (2010) 1.05
Quantification and characterisation of coronary artery plaque volume and adverse plaque features by coronary computed tomographic angiography: a direct comparison to intravascular ultrasound. Eur Radiol (2013) 1.05
Imaging of atherosclerosis. Annu Rev Med (2011) 1.04
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart (2007) 1.04
Incident coronary artery calcium among postmenopausal women. Atherosclerosis (2008) 1.02
Assessment of coronary plaque progression in coronary computed tomography angiography using a semiquantitative score. JACC Cardiovasc Imaging (2009) 1.01
Premenopausal risk factors for coronary and aortic calcification: a 20-year follow-up in the healthy women study. Prev Med (2007) 1.01
Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med (2015) 1.01
Lipid-lowering therapy: who can benefit? Vasc Health Risk Manag (2011) 1.01
Reproducibility of volumetric intravascular ultrasound radiofrequency-based analysis of coronary plaque composition in vivo. Int J Cardiovasc Imaging (2008) 1.01
Vascular ultrasound for atherosclerosis imaging. Interface Focus (2011) 1.00
Chronic coronary artery disease: diagnosis and management. Mayo Clin Proc (2009) 1.00
Atherosclerosis as a disease of failed endogenous repair. Front Biosci (2008) 1.00
Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovasc Diabetol (2013) 0.99
Impacts of age on coronary atherosclerosis and vascular response to statin therapy. Heart Vessels (2013) 0.99
Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care (2012) 0.97
Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging. Atherosclerosis (2007) 0.97
Angiography underestimates peripheral atherosclerosis: lumenography revisited. J Endovasc Ther (2008) 0.96
Reproducibility of computed tomography angiography data analysis using semiautomated plaque quantification software: implications for the design of longitudinal studies. Int J Cardiovasc Imaging (2012) 0.96
Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol (2012) 0.96
Imaging Atherosclerosis. Circ Res (2016) 0.95
Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation. PLoS One (2008) 0.95
Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment. EBioMedicine (2016) 0.95
Effect of statin therapy on the progression of coronary atherosclerosis. BMC Cardiovasc Disord (2012) 0.94
The fat-fed apolipoprotein E knockout mouse brachiocephalic artery in the study of atherosclerotic plaque rupture. J Biomed Biotechnol (2010) 0.94
MRI of atherosclerosis: diagnosis and monitoring therapy. Expert Rev Cardiovasc Ther (2007) 0.93
Soluble epoxide hydrolase in atherosclerosis. Curr Atheroscler Rep (2010) 0.93
Dominant-negative mutation of monocyte chemoattractant protein-1 prevents vulnerable plaques from rupture in rabbits independent of serum lipid levels. J Cell Mol Med (2008) 0.93
Effect of atorvastatin therapy on borderline vulnerable lesions in patients with acute coronary syndrome. Arch Med Sci (2011) 0.92
Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. CMAJ (2011) 0.92
Optical Coherence Tomography: Potential Clinical Applications. Curr Cardiovasc Imaging Rep (2012) 0.91
High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Cardiovasc Diabetol (2012) 0.90
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J (2011) 0.90
Plasma cholesterol-induced lesion networks activated before regression of early, mature, and advanced atherosclerosis. PLoS Genet (2014) 0.89
The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences. Vasc Health Risk Manag (2009) 0.89
Influence of statin treatment on coronary atherosclerosis visualised using multidetector computed tomography. Eur Radiol (2010) 0.88
Focus on the research utility of intravascular ultrasound - comparison with other invasive modalities. Cardiovasc Ultrasound (2011) 0.88
An integrated approach for the mechanisms responsible for atherosclerotic plaque regression. Exp Clin Cardiol (2011) 0.88
Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome. J Clin Endocrinol Metab (2007) 0.88
The diagnostic and prognostic value of coronary CT angiography in asymptomatic high-risk patients: a cohort study. Open Heart (2014) 0.88
Assessment of coronary atherosclerosis by IVUS and IVUS-based imaging modalities: progression and regression studies, tissue composition and beyond. Int J Cardiovasc Imaging (2011) 0.87
Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes. J Lipid Res (2009) 0.87
How can we further improve the LDL-cholesterol target level achievement rate based on the Hungarian MULTI GAP 2011 study results and considering the new European dyslipidemia guidelines? Arch Med Sci (2012) 0.87
Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients. Can J Cardiol (2006) 0.87
Noninvasive Imaging of Atherosclerotic Plaque Progression: Status of Coronary Computed Tomography Angiography. Circ Cardiovasc Imaging (2015) 0.86
Using clinical cardiovascular risk scores to predict coronary artery plaque severity and stenosis detected by CT coronary angiography in asymptomatic Chinese subjects. Int J Cardiovasc Imaging (2011) 0.86
Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk. Vasc Health Risk Manag (2009) 0.86
Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA). BMJ Open (2015) 0.85
Rapid regression of atherosclerosis with MTP inhibitor treatment. Atherosclerosis (2013) 0.85
Coronary CT angiography in the quantitative assessment of coronary plaques. Biomed Res Int (2014) 0.85
Different Plaque Composition and Progression in Patients with Stable and Unstable Coronary Syndromes Evaluated by Cardiac CT. Biomed Res Int (2015) 0.84
Efficacy of Statin Therapy in Inducing Coronary Plaque Regression in Patients with Low Baseline Cholesterol Levels. J Atheroscler Thromb (2016) 0.84
Stage-specific remodeling of atherosclerotic lesions upon cholesterol lowering in LDL receptor knockout mice. Am J Pathol (2011) 0.84
Efficacy and safety of rosuvastatin in the management of dyslipidemia. Vasc Health Risk Manag (2009) 0.84
The anti-ischemic and anti-anginal properties of statins. Curr Atheroscler Rep (2011) 0.84
Epigenome-guided analysis of the transcriptome of plaque macrophages during atherosclerosis regression reveals activation of the Wnt signaling pathway. PLoS Genet (2014) 0.84
Impact of combined lipid lowering with blood pressure control on coronary plaque regression: rationale and design of MILLION study. Heart Vessels (2014) 0.83
A predictor of atheroma progression in patients achieving very low levels of low-density lipoprotein cholesterol. Am J Cardiovasc Dis (2013) 0.83
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med (2010) 22.04
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med (2011) 15.70
Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med (2012) 13.59
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med (2007) 11.51
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med (2014) 10.66
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA (2003) 10.55
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science (2009) 10.47
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA (2004) 9.91
The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006) 9.61
Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA (2002) 8.81
Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 8.65
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J (2004) 7.84
Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 6.79
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet (2010) 6.23
T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation (2007) 6.23
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 6.12
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA (2007) 6.02
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA (2007) 5.89
Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89
Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol (2010) 5.79
Comparison of the instructional efficacy of Internet-based CME with live interactive CME workshops: a randomized controlled trial. JAMA (2005) 5.50
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes (2003) 5.43
Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41
Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation (2011) 4.78
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med (2005) 4.64
Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med (2003) 4.61
Lyme borreliosis. Lancet Infect Dis (2003) 4.58
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care (2005) 4.38
Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation (2002) 4.31
Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med (2007) 4.30
An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med (2006) 4.23
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA (2005) 4.23
Egg yolk consumption and carotid plaque. Atherosclerosis (2012) 4.20
The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol (2008) 4.20
Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med (2013) 4.14
Resting heart rate in cardiovascular disease. J Am Coll Cardiol (2007) 4.14
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med (2014) 4.14
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet (2009) 4.10
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (2004) 4.08
Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem (2008) 4.08
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J (2005) 4.06
Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation (2006) 3.99
Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med (2009) 3.97
Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care (2005) 3.96
Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol (2011) 3.95
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J (2011) 3.93
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Chronic hyperglycemia and subclinical myocardial injury. J Am Coll Cardiol (2012) 3.91
Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med (2006) 3.90
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation (2007) 3.85
Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med (2010) 3.79
Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation (2010) 3.72
Cerebral embolization during transcatheter aortic valve implantation: a transcranial Doppler study. Circulation (2012) 3.70